Paul Chaplin has resigned as CEO of Bavarian Nordic after the company's $3 billion merger deal with a U.S.-based defense conglomerate fell through. The failure marks a major setback for the Danish biotech firm, triggering immediate market reactions in its stock and broader biotech and defense sectors.
- Paul Chaplin resigned as CEO of Bavarian Nordic A/S following the collapse of a $3 billion merger deal.
- The acquisition was with a U.S.-based defense contractor and was terminated over regulatory and national security concerns.
- BVDNF stock fell 14% post-announcement, losing over $1.2 billion in market value.
- XBI ETF declined 2.1%, with defense-linked biotech stocks like LHX underperforming.
- Bavarian Nordic is now focusing on internal R&D and licensing opportunities.
- The board has launched a CEO search with emphasis on defense-biotech integration experience.
Paul Chaplin has stepped down as CEO of Bavarian Nordic A/S, the Copenhagen-based biotech firm, just weeks after the collapse of a planned $3 billion acquisition by a U.S.-based defense contractor. The proposed transaction, which had been under negotiation since late 2025, was terminated due to regulatory hurdles and concerns over national security reviews, particularly regarding the company’s advanced viral vector vaccine platform used in both pandemic preparedness and military bio-defense applications. The failed deal has had an immediate impact on investor sentiment. Bavarian Nordic’s stock, traded under the ticker BVDNF, dropped 14% in the two trading days following the announcement, erasing over $1.2 billion in market capitalization. The broader biotech sector, tracked by the XBI ETF, saw a 2.1% decline, with defense-linked biotech stocks like LHX experiencing disproportionate sell-offs. Industry analysts note that the failed merger has raised questions about the future of cross-border strategic partnerships in sensitive biotech domains. The departure of Chaplin, who led the company since 2018, coincides with a strategic pivot toward internal R&D and potential licensing deals. The board has initiated a search for a new CEO with expertise in both biotechnology innovation and defense-sector integration. Meanwhile, Bavarian Nordic continues to advance its TVEC-based vaccine candidates, including a next-generation smallpox vaccine currently in Phase 3 trials. The event underscores the growing complexity of merging biotech innovation with national security infrastructure. As global demand for rapid-response vaccines and bio-defense capabilities rises, companies operating at this intersection face heightened scrutiny and strategic uncertainty. The fallout from this failed deal may influence how similar transactions are structured in the future.